Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 1703880 + Ezabenlimab in Advanced Solid Tumours
NCT05471856Phase 1Recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Feb 2023
- Primary completion
- Sep 2028
- Modality
- Orthosteric Ligands
- Countries
- 6
01
Overview
Phase 1, open-label, single-arm trial of BI 1703880 in solid tumor, sponsored by Boehringer Ingelheim. Primary endpoint: Dose Limiting Toxicities at 6 weeks. Started Feb 2023; status: recruiting.
02
Drugs
BI 1703880
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05471856.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05471856.